Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Portfolio Pulse from Avi Kapoor
Wall Street analysts have updated their price targets and ratings for several companies. Karuna Therapeutics' target was raised but downgraded to Neutral. AlloVir's target was cut significantly and downgraded to Underperform. Farmland Partners, Huntington Bancshares, Cognizant Technology Solutions, Modine Manufacturing, and CMS Energy had their targets raised with positive ratings. Paychex and Omega Healthcare Investors had their targets cut with neutral and hold ratings, respectively. Equillium's target was slashed but maintained a Buy rating.
December 26, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CMS Energy's target was raised from $61 to $64 with an Outperform rating by BMO Capital.
The price target increase and positive rating suggest a favorable short-term impact on the stock.
CONFIDENCE 80
IMPORTANCE 55
RELEVANCE 65
POSITIVE IMPACT
Cognizant Technology Solutions' target was increased from $75 to $85 with an Outperform rating by Wedbush.
The target raise and positive rating suggest a strong positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Farmland Partners' price target was increased from $14 to $15 with an Outperform rating maintained by Raymond James.
The price target increase and continued Outperform rating suggest a positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Huntington Bancshares' target was raised from $13 to $15 with a Strong Buy rating by Raymond James.
The increased price target and Strong Buy rating indicate a positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 75
POSITIVE IMPACT
Modine Manufacturing's target was increased from $60 to $80 with a Buy rating by DA Davidson.
The substantial price target increase and Buy rating indicate a positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Equillium's price target was reduced from $4.5 to $4, but HC Wainwright & Co. maintained a Buy rating.
The price target cut is negative, but the maintained Buy rating could offset the impact, leading to a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 55
RELEVANCE 65
NEUTRAL IMPACT
Karuna Therapeutics' price target was raised from $300 to $330, but the stock was downgraded from Buy to Neutral by HC Wainwright & Co.
The price target increase is positive, but the downgrade suggests limited upside potential, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Omega Healthcare Investors' target was reduced from $34 to $31 with a Hold rating by Truist Securities.
A modest target reduction with a Hold rating suggests a neutral short-term impact on the stock.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
NEUTRAL IMPACT
Paychex's price target was cut from $130 to $125, but Citigroup maintained a Neutral rating.
A slight price target decrease with a maintained Neutral rating indicates a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
NEGATIVE IMPACT
AlloVir's price target was cut from $17 to $1 and downgraded from Buy to Underperform by B of A Securities.
A significant price target cut and a downgrade to Underperform indicate a strong negative short-term impact on the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 90